An improved version of an immunotherapy drug has demonstrated significant potential in combatting aggressive cancers during phase-1 trials, researchers report. CD40 agonist antibodies, a category of cancer therapeutics known for activating the immune system against cancer cells in animal models, have historically been associated with severe side effects such as systemic inflammatory responses, low platelet counts, and liver toxicity in human subjects, even at low dosages. In 2018, a group of researchers at the Rockefeller University in the United States enhanced the CD40 agonist antibody to augment its effectiveness while mitigating its adverse reactions.
The outcomes of the Phase I clinical trial of this upgraded drug, referred to as 2141-V11, were encouraging. Among the 12 patients involved in the trial, six witnessed a reduction in tumor size, with two experiencing complete disappearance of their tumors. Juan Osorio, a medical oncologist at Memorial Sloan Kettering Cancer Center and the first author of the study, expressed astonishment at the substantial tumor shrinkages and instances of complete remission observed in a small subset of patients. Noteworthy was the fact that the therapeutic impact extended beyond the locally injected tumors, leading to reductions in size or elimination of tumors elsewhere in the body by immune cells, as detailed in the findings published in the journal Cancer Cell.
The CD40 protein, a receptor located on cell surfaces and a member of the tumor necrosis factor receptor superfamily primarily found in immune cells, plays a pivotal role in triggering immune responses against cancer cells. The enhanced 2141-V11, developed by Ravetch’s team in 2018, is a CD40 antibody engineered to bind strongly to human CD40 receptors and modified to enhance its immune-stimulating abilities by engaging a specific Fc receptor. This modification rendered the antibody ten times more potent in eliciting an anti-tumor immune response. The drug was administered directly into tumors after being delivered intravenously to the patients, who were diagnosed with melanoma, renal cell carcinoma, and various types of breast cancer.
Remarkably, none of the 12 patients experienced the severe side effects commonly associated with other CD40 drugs. Six patients exhibited systemic tumor reduction, with two individuals diagnosed with melanoma and breast cancer achieving complete remission. These cancer types are notoriously aggressive and prone to recurrence, making the achievement of complete remission particularly significant in these cases. The ability of the enhanced CD40 agonist antibody to induce a systemic immune response following local administration represents a rare phenomenon in clinical treatments, underscoring the promising and unexpected outcomes of the trial conducted by Rockefeller University researchers.
Key Takeaways:
– Enhanced CD40 agonist antibodies have shown promising results in phase-1 trials for treating aggressive cancers by inducing systemic immune responses against tumors.
– The modified CD40 antibody, 2141-V11, demonstrated enhanced efficacy in shrinking tumors and triggering complete remission in certain patients without causing severe side effects.
– By targeting the CD40 receptor and engaging a specific Fc receptor, the engineered antibody proved to be ten times more potent in stimulating anti-tumor immune responses.
– The study’s findings highlight the potential of this immunotherapeutic approach in effectively combating aggressive cancers and achieving significant clinical responses.
Tags: immunotherapy
Read more on thehansindia.com